Skip to content Skip to footer
Subscribe Now
Viewpoints_Fred Aslan
VIEWPOINTS

Enhancing Care with NK Cell Therapy: Fred Aslan from Artiva Biotherapeutics in Conversation with PharmaShots

Shots:  Immune reset in oncology has been observed with approved autologous CAR-T products. A recent study published in Nature demonstrated B-cell reconstitution and immune reset in systemic lupus erythematosus (SLE) patients treated with a CD19 autologous CAR-T, showcasing promising potential in autoimmune diseases  Today, at PharmaShots, we have Fred Aslan shedding light on Artiva's AlloNK,…
November 4, 2024

Read more

Prescription Drugs Top 20 2024
TOP 20

Top 20 Prescription Drugs of 2024

Shots: Driven by an endless pursuit of innovation, the biopharma industry is working tirelessly to bring new-age therapies to patients with serious health conditions and lifestyle-influenced diseases In 2023, the global prescription drug market size was valued at $1162.61B and is anticipated to reach $2151.63B by 2032 registering a CAGR of 7.1 %. Keytruda ranks 1st…
October 31, 2024

Read more

Viewpoints_Adityo Prakash
VIEWPOINTS

AI in Drug Discovery: Adityo Prakash from Verseon in an Illuminating Dialogue Exchange with PharmaShots

Shots:  AI is widely used in drug discovery and clinical research to find innovative cures for several debilitating conditions with unmet healthcare needs  Most of the AI architecture employs deep learning that requires extensive training data sets to produce reliable predictive models  Today, at PharmaShots, we have Adityo Prakash, CEO of Verseon, addressing the challenges…
October 30, 2024

Read more

Viewpoints_Mina Makar
VIEWPOINTS

AstraZeneca at ERA’24: Mina Makar in a Stimulating Conversation with PharmaShots

Shots:  Recently, AstraZeneca presented findings from the real-world IMPACT CKD study, which evaluated the multifaceted impact of CKD on patients, healthcare systems, and broader society, projecting future implications through 2032.  The study emphasizes the importance of mitigating the economic burden on healthcare by implementing early, targeted screening, diagnosis, and treatment for CKD.  In collaboration with…
October 28, 2024

Read more

Viewpoints_Baldo Scassellati Sforzolini
VIEWPOINTS

Unlocking Approval: Baldo Scassellati Sforzolini from Galderma in a Stimulating Dialogue Exchange with PharmaShots

Shots:  Galderma’s Nemluvio (nemolizumab) was recently approved by the US FDA for the treatment of adults with prurigo nodularis, following positive Phase III results from the OLYMPIA study.  Today at PharmaShots, we have Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma, to discuss the study’s design and the potential of Nemluvio in…
October 23, 2024

Read more

Viewpoints_Mark Mikhael
VIEWPOINTS

Enhancing Accessibility: Mark Mikhael from Olympia Pharmaceuticals in a Riveting Conversation with PharmaShots

Shots:  Compounding pharmacies can help significantly by providing customized medications tailored to individual patient needs, bridging the gap in medicine delivery during a drug shortage, and enhancing accessibility.   Today, at PharmaShots, we have Mark Mikhael, CEO of Olympia Pharmaceuticals, an FDA-registered 503B outsourcing facility.  Currently licensed in 47 states of the US, Olympia hosts two…
October 21, 2024

Read more

ThoughtSpot_Fatima Batool
THOUGHTSPOT

Ohio Study Finds that Thousands of US Communities Are In a “Pharmacy Desert”

The recently hugely reduced number of pharmacies in many areas of the US—due to more frequently occurring pharmacy closures—is creating a phenomenon known as “pharmacy deserts.”  Concerningly, pharmacy deserts affect the ability of local communities to access affordable pharmacy resources in their vicinity. This can cause healthcare disparities between socioeconomic groups and, worse, impair the…
October 18, 2024

Read more

Know Your Investor- Samsara Biocapital (October’24 Edition)
INSIGHTS+

Know Your Investor: Samsara Biocapital (October’24 Edition)

Shots:   A California-based venture capital fund, Samsara Biocapital partners with medical companies and scientists to infuse cutting-edge innovations in medicines   In 2023, Samsara participated in five funding rounds and invested around $2.3B to add 19 companies to its portfolio   For a curated report on a specific investor or venture capital, reach out to us at connect@pharmashots.com …
October 17, 2024

Read more

Disease of the Month – Psoriatic arthritis
INSIGHTS+

Disease of the Month – Psoriatic arthritis

Shots: Psoriatic arthritis is a chronic inflammatory condition characterized by joint pain, stiffness and swelling  In this reprise of our Disease of the Month report, we present an enlightening description of Psoriatic arthritis with a thorough study of epidemiology, market size, disease management, potential medicines, patient advocacy groups, and the key players involved     For a…
October 16, 2024

Read more

Load more